(Dmt1)DALDA

Wait 5 sec.

← Previous revisionRevision as of 01:30, 18 November 2026 Line 48: Line 48: }} }} '''[Dmt1]DALDA''' ('''DMT-DALDA''', '''H-Dmt-D-Arg-Phe-Lys-NH2''') is a synthetic [[peptide]] which acts as a potent and selective agonist of the [[mu opioid receptor]]. It is a derivative of [[DALDA]], a synthetic opioid peptide developed as a metabolically stable analogue of the natural product [[dermorphin]], but with the [[tyrosine]] residue of DALDA replaced by 2,6-dimethyltyrosine, which allows it to cross the [[blood-brain barrier]] and produce centrally mediated opioid effects. It has been encountered as a [[designer drug]], mainly as a doping agent in [[racehorse]]s in competition. A wide range of related opioid peptides have subsequently been developed.{{cite journal | vauthors = Schiller PW, Nguyen TM, Berezowska I, Dupuis S, Weltrowska G, Chung NN, Lemieux C | title = Synthesis and in vitro opioid activity profiles of DALDA analogues | journal = European Journal of Medicinal Chemistry | volume = 35 | issue = 10 | pages = 895–901 | date = October 2000 | pmid = 11121615 | doi = 10.1016/s0223-5234(00)01171-5 }}{{cite journal | vauthors = Shimoyama M, Shimoyama N, Zhao GM, Schiller PW, Szeto HH | title = Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 297 | issue = 1 | pages = 364–371 | date = April 2001 | doi = 10.1016/S0022-3565(24)29547-1 | pmid = 11259564 }}{{cite journal | vauthors = Neilan CL, Nguyen TM, Schiller PW, Pasternak GW | title = Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide | journal = European Journal of Pharmacology | volume = 419 | issue = 1 | pages = 15–23 | date = May 2001 | pmid = 11348625 | doi = 10.1016/s0014-2999(01)00946-3 }}{{cite journal | vauthors = Schiller PW | title = Opioid peptide-derived analgesics | journal = The AAPS Journal | volume = 7 | issue = 3 | pages = E560–E565 | date = October 2005 | pmid = 16353933 | doi = 10.1208/aapsj070356 | pmc = 2751258 }}Balboni G, Cocco MT, Salvadori S, Romagnoli R, Sasaki Y, Okada Y, Bryant SD, Jinsmaa Y, Lazarus LH. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. ''J Med Chem''. 2005 Aug 25;48(17):5608-11. {{doi|10.1021/jm0504959}} {{pmid|16107162}}{{cite journal | vauthors = Schiller PW | title = Bi- or multifunctional opioid peptide drugs | journal = Life Sciences | volume = 86 | issue = 15–16 | pages = 598–603 | date = April 2010 | pmid = 19285088 | doi = 10.1016/j.lfs.2009.02.025 | pmc = 2848892 }}{{cite journal | vauthors = Shimoyama M, Schiller PW, Shimoyama N, Toyama S, Szeto HH | title = Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain | journal = Chemical Biology & Drug Design | volume = 80 | issue = 5 | pages = 771–774 | date = November 2012 | pmid = 22834682 | doi = 10.1111/cbdd.12003 | pmc = 3465489 }}Novoa A, Van Dorpe S, Wynendaele E, Spetea M, Bracke N, Stalmans S, Betti C, Chung NN, Lemieux C, Zuegg J, Cooper MA, Tourwé D, De Spiegeleer B, Schiller PW, Ballet S. Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution. ''J Med Chem''. 2012 Nov 26;55(22):9549-61. {{doi|10.1021/jm3008079}} {{pmid|23102273}}{{cite journal | vauthors = Dumitrascuta M, Bermudez M, Ballet S, Wolber G, Spetea M | title = Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the mu Opioid Receptor | journal = Molecules | volume = 25 | issue = 9 | date = April 2020 | page = 2087 | pmid = 32365707 | doi = 10.3390/molecules25092087 | pmc = 7248707 | doi-access = free }}{{cite journal | vauthors = Choi TL, Lau MY, Wong JK, Wan TS, Ho EN | title = Identification of the dermorphin tetrapeptide [Dmt1 ]-DALDA in a seized unlabelled vial and its first detection in horse urine: A case report | journal = Drug Testing and Analysis | volume = 16 | issue = 3 | pages = 268–276 | date = March 2024 | pmid = 37408356 | doi = 10.1002/dta.3536 }} '''[Dmt1]DALDA''' ('''DMT-DALDA''', '''H-Dmt-D-Arg-Phe-Lys-NH2''') is a synthetic [[peptide]] which acts as a potent and selective agonist of the [[mu opioid receptor]]. It is a derivative of [[DALDA]], a synthetic opioid peptide developed as a metabolically stable analogue of the natural product [[dermorphin]], but with the [[tyrosine]] residue of DALDA replaced by 2,6-dimethyltyrosine, which allows it to cross the [[blood-brain barrier]] and produce centrally mediated opioid effects. It has been encountered as a [[designer drug]], mainly as a doping agent in [[racehorse]]s in competition. A wide range of related opioid peptides have subsequently been developed.{{cite journal | vauthors = Schiller PW, Nguyen TM, Berezowska I, Dupuis S, Weltrowska G, Chung NN, Lemieux C | title = Synthesis and in vitro opioid activity profiles of DALDA analogues | journal = European Journal of Medicinal Chemistry | volume = 35 | issue = 10 | pages = 895–901 | date = October 2000 | pmid = 11121615 | doi = 10.1016/s0223-5234(00)01171-5 }}{{cite journal | vauthors = Shimoyama M, Shimoyama N, Zhao GM, Schiller PW, Szeto HH | title = Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 297 | issue = 1 | pages = 364–371 | date = April 2001 | doi = 10.1016/S0022-3565(24)29547-1 | pmid = 11259564 }}{{cite journal | vauthors = Neilan CL, Nguyen TM, Schiller PW, Pasternak GW | title = Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide | journal = European Journal of Pharmacology | volume = 419 | issue = 1 | pages = 15–23 | date = May 2001 | pmid = 11348625 | doi = 10.1016/s0014-2999(01)00946-3 }}{{cite journal | vauthors = Schiller PW | title = Opioid peptide-derived analgesics | journal = The AAPS Journal | volume = 7 | issue = 3 | pages = E560–E565 | date = October 2005 | pmid = 16353933 | doi = 10.1208/aapsj070356 | pmc = 2751258 }}Balboni G, Cocco MT, Salvadori S, Romagnoli R, Sasaki Y, Okada Y, Bryant SD, Jinsmaa Y, Lazarus LH. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. ''J Med Chem''. 2005 Aug 25;48(17):5608-11. {{doi|10.1021/jm0504959}} {{pmid|16107162}}{{cite journal | vauthors = Schiller PW | title = Bi- or multifunctional opioid peptide drugs | journal = Life Sciences | volume = 86 | issue = 15–16 | pages = 598–603 | date = April 2010 | pmid = 19285088 | doi = 10.1016/j.lfs.2009.02.025 | pmc = 2848892 }}{{cite journal | vauthors = Shimoyama M, Schiller PW, Shimoyama N, Toyama S, Szeto HH | title = Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain | journal = Chemical Biology & Drug Design | volume = 80 | issue = 5 | pages = 771–774 | date = November 2012 | pmid = 22834682 | doi = 10.1111/cbdd.12003 | pmc = 3465489 }}Novoa A, Van Dorpe S, Wynendaele E, Spetea M, Bracke N, Stalmans S, Betti C, Chung NN, Lemieux C, Zuegg J, Cooper MA, Tourwé D, De Spiegeleer B, Schiller PW, Ballet S. Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution. ''J Med Chem''. 2012 Nov 26;55(22):9549-61. {{doi|10.1021/jm3008079}} {{pmid|23102273}}Turnaturi R, Aricò G, Ronsisvalle G, Parenti C, Pasquinucci L. Multitarget opioid ligands in pain relief: New players in an old game. ''Eur J Med Chem''. 2016 Jan 27;108:211-228. {{doi|10.1016/j.ejmech.2015.11.028}} {{pmid|26656913}}Cai Y, Lu D, Chen Z, Ding Y, Chung NN, Li T, Schiller PW. [Dmt(1)]DALDA analogues modified with tyrosine analogues at position 1. ''Bioorg Med Chem Lett''. 2016 Aug 1;26(15):3629-31. {{doi|10.1016/j.bmcl.2016.06.003}} {{pmid|27301366}}{{cite journal | vauthors = Dumitrascuta M, Bermudez M, Ballet S, Wolber G, Spetea M | title = Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the mu Opioid Receptor | journal = Molecules | volume = 25 | issue = 9 | date = April 2020 | page = 2087 | pmid = 32365707 | doi = 10.3390/molecules25092087 | pmc = 7248707 | doi-access = free }}Smith MT, Kong D, Kuo A, Imam MZ, Williams CM. Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources. ''J Med Chem''. 2022 Feb 10;65(3):1612-1661. {{doi|10.1021/acs.jmedchem.0c01915}} {{pmid|34995453}}{{cite journal | vauthors = Choi TL, Lau MY, Wong JK, Wan TS, Ho EN | title = Identification of the dermorphin tetrapeptide [Dmt1 ]-DALDA in a seized unlabelled vial and its first detection in horse urine: A case report | journal = Drug Testing and Analysis | volume = 16 | issue = 3 | pages = 268–276 | date = March 2024 | pmid = 37408356 | doi = 10.1002/dta.3536 }} == See also == == See also ==